In the tumor microenvironment, the PD-1 ligand, PD-L1, is upregulated by IFN-γ and other cytokines derived from infiltrating activated T cells and induces resistance to tumor T-cell immunity [144]. The gene discussed is IFNG; the disease is neoplasm.